Chemistry:BAN2401
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | Beta amyloid |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
Lecanemab also known as BAN2401 is an experimental drug that is currently in clinical trials for the treatment of Alzheimer's disease.[1] It is a humanized version[2] of a mouse antibody mAb158 that recognizes protofibrils and prevents amyloid beta deposition in animal models of Alzheimer's disease.[3]
References
- ↑ Clinical trial number NCT01767311 for "Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease" at ClinicalTrials.gov
- ↑ "Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease". Alzheimer's Research & Therapy 6 (2): 16. 2014. doi:10.1186/alzrt246. PMID 25031633.
- ↑ "The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death". Journal of Neuroinflammation 15 (1): 98. March 2018. doi:10.1186/s12974-018-1134-4. PMID 29592816.
 |
